Notice NOT-NS-20-108 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-099 from the NIH Guide for Grants and Contracts

Notice NOT-OH-20-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-304 from the NIH Guide for Grants and Contracts. NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

Notice NOT-HS-20-016 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-168 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-109 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-21-015 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applicants to participate in a new NHLBI phenomics program, HeartShare: Next Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets (hereafter referred to as HeartShare). The goal of this program is to conduct large-scale analysis of phenotypic data, images, and omics from patients with heart failure with preserved ejection fraction (HFpEF) in order to characterize mechanisms of disease and identify therapeutic targets. This FOA solicits applications for Clinical Centers (CCs) that will recruit and retain heart failure patients and controls. CCs will participate in all aspects of planning and conducting a deep phenotyping protocol for HFpEF patients, as well as interpretation and translation of results. A companion FOA (RFA-HL-21-016 ) will support a Data Translation Center for overall coordination of the HeartShare program.

Funding Opportunity RFA-HL-21-016 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applicants to participate in a new NHLBI phenomics program, HeartShare: Next Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets (hereafter referred to as HeartShare). The goal of this program is to conduct large-scale analysis of phenotypic data, images, and omics from patients with heart failure with preserved ejection fraction (HFpEF) in order to characterize mechanisms of disease and identify therapeutic targets. This FOA solicits applications for a Data Translation Center (DTC) that will be responsible for overall project coordination, support development of a new cohort of HFpEF patients, and curate and analyze existing data from NIH cohorts and trials. A companion FOA (RFA-HL-21-015) will support the Clinical Centers.

Funding Opportunity PAR-20-291 from the NIH Guide for Grants and Contracts. The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.

Funding Opportunity PAR-20-290 from the NIH Guide for Grants and Contracts. The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Notice NOT-OD-20-164 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-173 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-300 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric ?precision therapeutics.

Funding Opportunity PAR-20-299 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.

Notice NOT-NS-20-038 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-071 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-101 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-20-506 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Urinary Stone Disease Research Network (USDRN) is conducting a multi-center randomized clinical trial and an observational clinical study to a) provide evidence on the effects of increased fluid intake and urine output on urinary stone disease recurrence through innovative adherence strategies, b) understand and mitigate ureteral stent-associated pain and urinary symptoms, and c) collect data and biological samples for future investigations. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to solicit applications from current USDRN Clinical Centers to complete these clinical investigations.